Risperidone Provides Better Improvement of Sleep Disturbances Than Haloperidol Therapy in Schizophrenia Patients With Cannabis-Positive Urinalysis

Autor: Clayton A. Sewell, Wendel D. Abel, Peta‐Gaye Latoya Thomas‐Brown, Maxine Gossell-Williams, Jacqueline S. Martin
Rok vydání: 2018
Předmět:
Zdroj: Frontiers in Pharmacology
Frontiers in Pharmacology, Vol 9 (2018)
ISSN: 1663-9812
DOI: 10.3389/fphar.2018.00769
Popis: A high percentage of persons with Schizophrenia also uses Cannabis and this may potentially alter the therapeutic benefits of the antipsychotic medications prescribed. The aim of this study was to assess the impact of Cannabis usage on antipsychotic therapy of sleep disturbances in schizophrenia subjects. Male subjects, ≥18 years, admitted to the University Hospital of the West Indies psychiatric ward between October 2015 and October 2016, and diagnosed with schizophrenia were recruited for the study. Following written informed consent to the study, subjects were prescribed either risperidone monotherapy or haloperidol monotherapy orally for 14 days and classified as Cannabis users (CU) or non-users (non-CU), with presence/absence of Cannabis metabolite in urine samples. After 1 week of admission, subjects wore the Actiwatch-2 device, to record sleep data for 7 consecutive nights. Inferential statistical analysis involved non-parametric tests, expressed as median and inter-quartile ranges (IQR), with p
Databáze: OpenAIRE